The Brazilian state of Parana signed a deal Wednesday to test and produce Russia's new coronavirus vaccine, though officials stressed they would have to be sure of its safety and effectiveness first.
|Military personnel from the Brazilian Armed Forces sanitizes a bus at the Santa Candida bus terminal to combat the spread of the the novel coronavirus, COVID-19, in Curitiba, Parana State, Brazil, on August 10, 2020. The pandemic has killed at least 731,518 people worldwide, 101,049 of them in Brazil, since it surfaced in China late last year, according to a tally from official sources compiled by AFP at 1100 GMT on Monday. (Photo: Daniel CASTELLANO / AFP) |
The vaccine would have to receive Brazilian regulatory approval and complete Phase 3 clinical trials, or large-scale testing in humans, before being produced in Brazil, said officials from the southern state.
Production, if it goes ahead, would likely only start in the second half of 2021, said Jorge Callado, head of the state-run Parana Technology Institute, which signed the deal with the Russian Direct Investment Fund (RDIF).
"This is a very objective memorandum of understanding on technological exchange. It does not impose obligations, it simply enables us to work together," he told a virtual news conference.
He said that under the deal Russia would share the results of Phase 1 and 2 testing with the state.
President Vladimir Putin announced Tuesday that Russia had approved the vaccine, dubbed "Sputnik V," in a world first, heralding it as a game-changer in the pandemic.
But international health officials have cautioned more testing and scrutiny are needed to ensure it is safe and effective.
Brazil has become a popular testing ground for COVID-19 vaccines, since the new coronavirus is still spreading quickly there.
The country has the second-highest number of infections and deaths in the pandemic, after the United States: more than 3.1 million and 104,000, respectively.
Two experimental vaccines are currently in Phase 3 testing in Brazil, one developed by Oxford University with pharmaceutical firm AstraZeneca and the other by Chinese laboratory Sinovac Biotech.